Agensys, Inc. engages in research and developing therapeutic fully human monoclonal antibodies (MAbs) to treat cancer. It develops products that include naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company develops AGS-1C4D4 for the treatment of pancreatic cancer; and various ADCs, such as AGS-16M8F, ASG-5ME, and ASG-22ME for treatment of various solid tumors. Agensys, Inc. was formerly known as UroGenesys, Inc. and changed its name to Agensys, Inc. in June 2001. The company was founded in 1996 and is based in Santa Monica, California. As of December 18, 20...
1800 Stewart Street
Santa Monica, CA 90404
Founded in 1996
Seattle Genetics and Agensys Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration
Jun 27 13
Seattle Genetics Inc. and Agensys, Inc. that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME. ASG-15ME is an ADC composed of a fully human antibody directed to SLITRK6, an antigen expressed in multiple solid tumors. Preclinically, ASG-15ME has demonstrated antitumor activity in models of bladder and lung cancer. The antibody is attached to a potent, synthetic cytotoxic agent, monomethyl auristatin E (MMAE), via an enzyme-cleavable linker using Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLITRK6-expressing tumor cells, resulting in targeted cell-killing. Upon the option exercise, Seattle Genetics will make an option exercise payment and thereafter fund half of the future development costs for the ASG-15ME program. The impact of the option exercise on Astellas' current fiscal year (from April 1, 2013, to March 31, 2014) financial forecast will be immaterial.